Yearbook

Pharma’s year end review for 2023

A look at major 2023 trends involving drug shortages, major biosimilar launches, rare disease drug development and the outlook for pharma in 2024

In association with

2023 review: the themes shaping year in the healthcare sector

Inside the hunt for an Alzheimer’s disease vaccine

NASH drugs race to cross the finish line

European nations struggle with drug shortages

02/23/2024 23:27:05
  • Home | Pharma’s path to Net Zero: Targeting Scope 3 emissions
  • Editor's letter
  • Contents
  • Mimotopes Company Insight
  • Mimotopes
  • Briefing
  • News in Numbers
  • Latest News
  • Latest Deals
  • Project Updates
  • Dycem
  • In Depth
  • Pharma’s path to Net Zero: Targeting Scope 3 emissions
  • Profit vs inquiry: Clash of objectives in academic and commercial trials
  • CTO Europe 2023: A snapshot of challenges and opportunities in oncology
  • The future of cell and gene therapy manufacturing
  • VPAS is dead, long live VPAG
  • Q&A: European Pharmaceutical legislation: hindrance or help?
  • Natoli
  • Nipro
  • Yearbook
  • Yearbook contents
  • UK’s pharma regulatory scene reckons with changes in 2023
  • Pharma breakthroughs: 10 novel drug approvals that made headlines in 2023
  • Top themes of 2023: AI, precision medicine, virtual care, digital therapeutics
  • Humira biosimilars set the stage for long-awaited 2023 US launches
  • Inside the hunt for an Alzheimer’s disease vaccine
  • Pathbreakers: The journey of first generics
  • NASH drugs race to cross the finish line
  • Fighting AMR with a value and subscription model
  • Cancer treatment uncertainty: European nations struggle with drug shortages
  • Why are haemophilia gene therapies so expensive?
  • Top themes for the healthcare sector in 2024
  • Listings
  • Events
  • The top 100 most innovative companies in the US in 2023
  • Buyer's Guides
  • Next issue
12/18/2023 00:00:00